Tilray Brands marked 4/20 by emphasizing its leadership in the medical cannabis sector and commitment to advancing patient care through a science-driven global platform. The company serves over 400,000 patients worldwide with pharmaceutical-grade medical cannabis products and continues to invest in clinical research, physician education, and distribution. With operations across multiple continents, Tilray is positioned to scale its patient-centric platform as regulatory frameworks evolve, especially in the U.S. This highlights Tilray's role in shaping the future growth of the global medical cannabis market.
The cannabis industry is expanding rapidly with cannabis now classified as a Class 3 substance, reducing legal barriers for operators. This shift allows for more research, product development, and growth opportunities for both cannabis producers and ...
Tilray Brands, a global leader in cannabis and consumer packaged goods, will announce its financial results for the fourth quarter and full fiscal year ending May 31, 2026, on July 28, 2026, after market close. The company will hold a live conference...
BrewDog Waterloo, England's largest pub owned by Tilray Brands, is set to host a major watch party for the England vs Argentina semifinal. The event promises an electric atmosphere with giant screens and passionate fans. Tilray's £1 million bar tab p...
